Literature DB >> 24351440

MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.

Banumathy Gowrishankar1, Ilsiya Ibragimova1, Yan Zhou2, Michael J Slifker2, Karthik Devarajan2, Tahseen Al-Saleem3, Robert G Uzzo4, Paul Cairns5.   

Abstract

Clear cell RCC is the most common, and more likely to metastasize, of the three main histological types of RCC. Pathologic stage is the most important prognostic indicator and nuclear grade can predict outcome within stages of localized RCC. Epithelial tumors are thought to accumulate a series of genetic and epigenetic changes as they progress through well-defined clinical and histopathological changes. MicroRNAs (miRNAs) are involved in the regulation of mRNA expression from many human genes and miRNA expression is dysregulated in cancer. To better understand the contribution of dysregulated miRNA expression to the progression and biology of ccRCC, we examined the differences in expression levels of 723 human miRNAs through a series of analyses by stage, grade, and disease progression status in a large series of 94 ccRCC. We found a consistent signature that included significant upregulation of miR-21-5p, 142-3p, let-7g-5p, let-7i-5p and 424-5p, as well as downregulation of miR-204-5p, to be associated with ccRCC of high stage, or high grade, or progression. Discrete signatures associated with each of stage, grade, or progression were also identified. The let-7 family was significantly downregulated in ccRCC compared with normal renal parenchyma. Expression of the 6 most significantly differentially expressed miRNAs between ccRCC was verified by stem-loop qRT-PCR. Pathways predicted as targets of the most significantly dysregulated miRNAs included signaling, epithelial cancers, metabolism, and epithelial to mesenchymal transition. Our studies help to further elucidate the biology underlying the progression of ccRCC and identify miRNAs for potential translational application.

Entities:  

Keywords:  RCC; clear cell RCC; expression; grade; miRNA; microRNA; progression; signatures; stage

Mesh:

Substances:

Year:  2013        PMID: 24351440      PMCID: PMC3974834          DOI: 10.4161/cbt.27314

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  51 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer.

Authors:  Regalla Kumarswamy; Giridhar Mudduluru; Paolo Ceppi; Santoshi Muppala; Miroslaw Kozlowski; Jacek Niklinski; Mauro Papotti; Heike Allgayer
Journal:  Int J Cancer       Date:  2011-08-08       Impact factor: 7.396

3.  Direct and sensitive miRNA profiling from low-input total RNA.

Authors:  Hui Wang; Robert A Ach; Bo Curry
Journal:  RNA       Date:  2006-11-14       Impact factor: 4.942

4.  Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis.

Authors:  Goutam Ghosh; Indira V Subramanian; Neeta Adhikari; Xiaoxiao Zhang; Hemant P Joshi; David Basi; Y S Chandrashekhar; Jennifer L Hall; Sabita Roy; Yan Zeng; Sundaram Ramakrishnan
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

5.  Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis.

Authors:  Angelika Kuehbacher; Carmen Urbich; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Circ Res       Date:  2007-05-31       Impact factor: 17.367

6.  MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens.

Authors:  Lihong Weng; Xiwei Wu; Hanlin Gao; Bing Mu; Xuejun Li; Jin-Hui Wang; Chao Guo; Jennifer M Jin; Zhuo Chen; Maricela Covarrubias; Yate-Ching Yuan; Lawrence M Weiss; Huiqing Wu
Journal:  J Pathol       Date:  2010-09       Impact factor: 7.996

7.  MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.

Authors:  Peter Olson; Jun Lu; Hao Zhang; Anny Shai; Matthew G Chun; Yucheng Wang; Steven K Libutti; Eric K Nakakura; Todd R Golub; Douglas Hanahan
Journal:  Genes Dev       Date:  2009-09-15       Impact factor: 11.361

8.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

9.  Identification of a microRNA panel for clear-cell kidney cancer.

Authors:  David Juan; Gabriela Alexe; Travis Antes; Huiqing Liu; Anant Madabhushi; Charles Delisi; Shridhar Ganesan; Gyan Bhanot; Louis S Liou
Journal:  Urology       Date:  2009-12-29       Impact factor: 2.649

10.  Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing.

Authors:  Susanne Osanto; Yongjun Qin; Henk P Buermans; Johannes Berkers; Evelyne Lerut; Jelle J Goeman; Hendrik van Poppel
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

View more
  45 in total

1.  MiR-514a-3p inhibits cell proliferation and epithelial-mesenchymal transition by targeting EGFR in clear cell renal cell carcinoma.

Authors:  Xinwen Ke; Xing Zeng; Xian Wei; Yuanqing Shen; Jiahua Gan; Huake Tang; Zhiquan Hu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  A tumor-specific microRNA signature predicts survival in clear cell renal cell carcinoma.

Authors:  Yu-Zheng Ge; Ran Wu; Hui Xin; Meng Zhu; Tian-Ze Lu; Hao Liu; Zheng Xu; Peng Yu; You-Cai Zhao; Ming-Hao Li; Zhi-Kai Hu; Yan Zhao; Bing Zhong; Xiao Xu; Liu-Hua Zhou; Lu-Wei Xu; Jian-Ping Wu; Wen-Cheng Li; Jia-Geng Zhu; Rui-Peng Jia
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-30       Impact factor: 4.553

3.  miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma.

Authors:  Qing-Zhi Long; Yue-Feng Du; Xiao-Gang Liu; Xiang Li; Da-Lin He
Journal:  Tumour Biol       Date:  2015-04-12

4.  MicroRNA-142-5p promotes cell growth and migration in renal cell carcinoma by targeting BTG3.

Authors:  Lingqi Liu; Shuchao Liu; Qixin Duan; Liang Chen; Tianpeng Wu; Huijun Qian; Sixing Yang; Dianqi Xin; Zhisong He; Yinglu Guo
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

5.  Global microRNA profiling for diagnostic appraisal of melanocytic Spitz tumors.

Authors:  Nicholas Latchana; Kelly Regan; J Harrison Howard; Jennifer H Aldrink; Mark A Ranalli; Sara B Peters; Xiaoli Zhang; Alejandro Gru; Philip R O Payne; Lorena P Suarez-Kelly; William E Carson
Journal:  J Surg Res       Date:  2016-07-04       Impact factor: 2.192

6.  MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma.

Authors:  Yulian Mytsyk; Victor Dosenko; Yuriy Borys; Askold Kucher; Katarina Gazdikova; Dietrich Busselberg; Martin Caprnda; Peter Kruzliak; Ammad Ahmad Farooqi; Manyuk Lubov
Journal:  Int Urol Nephrol       Date:  2018-03-16       Impact factor: 2.370

7.  Methylation and expression levels of microRNA-23b/-24-1/-27b, microRNA-30c-1/-30e, microRNA-301a and let-7g are dysregulated in clear cell renal cell carcinoma.

Authors:  I Gilyazova; E Ivanova; G Gilyazova; I Sultanov; A Izmailov; R Safiullin; V Pavlov; E Khusnutdinova
Journal:  Mol Biol Rep       Date:  2021-07-24       Impact factor: 2.316

Review 8.  Background, applications and challenges of radiogenomics in genitourinary tumor.

Authors:  Longfei Liu; Xiaoping Yi; Can Lu; Yingxian Pang; Xiongbing Zu; Minfeng Chen; Xiao Guan
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

9.  MicroRNA-30a-3p functions as a tumor suppressor in renal cell carcinoma by targeting WNT2.

Authors:  Lingqi Liu; Liang Chen; Tianpeng Wu; Huijun Qian; Sixing Yang
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

Review 10.  The roles of microRNAs in Wilms' tumors.

Authors:  Xin Yu; Zheng Li; Matthew T V Chan; William Ka Kei Wu
Journal:  Tumour Biol       Date:  2015-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.